Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer
Histopathology, 09/04/09
Wang Q et al. – The CD133 antigen has been identified as a putative stem cell marker in colorectal cancer tissues. According to the cancer stem cell hypothesis, CD133+ cells determine long–term tumour growth and are therefore suspected of influencing clinical outcome. CD133 stem cell antigen expression correlates with patient survival in rectal cancer, lending support to the current cancer stem cell hypothesis.
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma
American Journal of Clinical Nutrition, 10/29/09
Localized resection for colon cancer
Surgical Oncology, 11/04/09
Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies
Journal of Cancer Research & Clinical Oncology, 11/17/09
Sponsor
Article Search
Sponsor
Sponsor